| Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. Co.'s U.S. Food and Drug Administration approved commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA® (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. We show 27 historical shares outstanding datapoints in our PRTK shares outstanding history coverage, used to compute PRTK market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRTK market cap history over the course of time is important for investors
interested in comparing PRTK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRTK versus a peer is one thing; comparing
PRTK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRTK can fluctuate over the course of history.
With this page we aim to empower investors researching PRTK by allowing them to research the PRTK market cap history.